Intellia Therapeutics (NTLA) to Release Quarterly Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.8017) per share and revenue of $12.98 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. The company had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same period in the previous year, the business earned ($1.10) earnings per share. On average, analysts expect Intellia Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Intellia Therapeutics Trading Up 0.8%

Shares of NTLA stock opened at $10.77 on Tuesday. The stock has a market cap of $1.50 billion, a P/E ratio of -3.04 and a beta of 1.81. Intellia Therapeutics has a 1 year low of $7.95 and a 1 year high of $28.25. The stock has a 50 day simple moving average of $13.81 and a 200 day simple moving average of $13.51.

Insiders Place Their Bets

In other news, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares in the company, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Michael P. Dube sold 2,641 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the transaction, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This trade represents a 3.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC increased its position in Intellia Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after purchasing an additional 2,288,146 shares in the last quarter. State Street Corp boosted its position in Intellia Therapeutics by 29.1% in the fourth quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after buying an additional 1,447,967 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Intellia Therapeutics by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock worth $24,243,000 after buying an additional 107,333 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Intellia Therapeutics by 7.6% during the third quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock worth $42,305,000 after buying an additional 173,033 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Intellia Therapeutics by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,931,849 shares of the company’s stock worth $17,367,000 after buying an additional 174,555 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NTLA has been the subject of several analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, June 16th. Chardan Capital raised their price target on Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Sanford C. Bernstein boosted their price target on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Leerink Partners set a $35.00 price objective on shares of Intellia Therapeutics in a research report on Monday, April 27th. Finally, Morgan Stanley increased their price objective on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $20.19.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.